Increased expression of atrogenes and TWEAK family members after severe burn injury in nonburned human skeletal muscle

Journal of Burn Care and Research

Volumn 34, Issue 5, 2013, Pages

  Merritt, Edward K ^a   Thalacker Mercer, Anna ^a   Cross, James M ^b   Windham, Samuel T ^c   Thomas, Steven J ^b   Bamman, Marcas M ^a,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c University of Alabama at Birmingham   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; MESSENGER RNA; MUSCLE RING FINGER 1 PROTEIN; PROTEASOME; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR RECEPTOR 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE;

ADULT; BIOPSY, NEEDLE; BODY SURFACE AREA; BURNS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA, MESSENGER; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SKP CULLIN F-BOX PROTEIN LIGASES; TUMOR NECROSIS FACTORS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION; YOUNG ADULT;

EID: 84885314481     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e31827a2a9c     Document Type: Article

References (50)

1. Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000;128:312-9.
2. Chandra RK. Nutrition and immunology: from the clinic to cellular biology and back again. Proc Nutr Soc 1999;58:681-3.
3. Wilmore DW. Catabolic illness. Strategies for enhancing recovery. N Engl J Med 1991;325:695-702.
4. Zaloga GP, Roberts PR. Early enteral feeding improves outcome. In: Vincent JL, editor. Yearbook of intensive care and emergency medicine. Berlin, Germany: Springer-Verlag; 1997. p. 701-14.
5. Pereira C, Murphy K, Jeschke M, Herndon DN. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005;37:1948-61.
6. Sayeed MM. Signaling mechanisms of altered cellular responses in trauma, burn, and sepsis: role of Ca2+. Arch Surg 2000;135:1432-42.
7. Hart DW, Wolf SE, Chinkes DL, et al. Determinants of skeletal muscle catabolism after severe burn. Ann Surg 2000;232:455-65.
8. Rutan RL, Herndon DN. Growth delay in postburn pediatric patients. Arch Surg 1990;125:392-5.
9. Fang CH, Li BG, James JH, et al. Protein breakdown in muscle from burned rats is blocked by insulin-like growth factor i and glycogen synthase kinase-3beta inhibitors. Endocrinology 2005;146:3141-9.
10. Lang CH, Huber D, Frost RA. Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol 2007;292:R328-36.
11. Kandarian SC, Jackman RW. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 2006;33:155-65.
12. Merritt EK, Cross JM, Bamman MM. Inflammatory and protein metabolism signaling responses in human skeletal muscle after burn injury. J Burn Care Res 2012;33:291-7.
13. Doucet M, Russell AP, Léger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:261-9.
14. Gustafsson T, Osterlund T, Flanagan JN, et al. Effects of 3 days unloading on molecular regulators of muscle size in humans. J Appl Physiol 2010;109:721-7.
15. Larsen AE, Tunstall RJ, Carey KA, et al. Actions of short-term fasting on human skeletal muscle myogenic and atrogenic gene expression. Ann Nutr Metab 2006;50:476-81.
16. Levine S, Biswas C, Dierov J, et al. Increased proteolysis, myosin depletion, and atrophic AKT-FOXO signaling in human diaphragm disuse. Am J Respir Crit Care Med 2011;183:483-90.
17. Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol A Biol Sci Med Sci 2007;62:1407-12.
18. Degens H, Alway SE. Control of muscle size during disuse, disease, and aging. Int J Sports Med 2006;27:94-9.
19. Späte U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7:265-9.
20. Li H, Malhotra S, Kumar A. Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med 2008;86:1113-26.
21. Finnerty CC, Herndon DN, Przkora R, et al. Cytokine expression profile over time in severely burned pediatric patients. Shock 2006;26:13-9.
22. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005;98:911-7.
23. Warren RS, Starnes HF Jr, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396-400.
24. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007;21:1857-69.
25. Tuvdendorj D, Chinkes DL, Zhang XJ, Sheffield-Moore M, Herndon DN. Skeletal muscle is anabolically unresponsive to an amino acid infusion in pediatric burn patients 6 months postinjury. Ann Surg 2011;253:592-7.
26. Evans WJ, Phinney SD, Young VR. Suction applied to a muscle biopsy maximizes sample size. Med Sci Sports Exerc 1982;14:101-2.
27. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8.
28. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-5.
29. Lecker SH. Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways? Curr Opin Clin Nutr Metab Care 2003;6:271-5.
30. Cohen S, Brault JJ, Gygi SP, et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009;185:1083-95.
31. Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, Leibovitch SA. Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS ONE 2009;4:e4973.
32. Lagirand-Cantaloube J, Offner N, Csibi A, et al. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J 2008;27: 1266-76.
33. Fareed MU, Evenson AR, Wei W, et al. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 2006;290:R1589-97.
34. Bhatnagar S, Mittal A, Gupta SK, Kumar A. TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. J Cell Physiol 2012;227:1042-51
35. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAKindependent functions of Fn14 during myogenesis. J Biol Chem 2007;282:15000-10.
36. Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A. TNFlike weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase J Immunol 2009;182:2439-48.
37. Mittal A, Bhatnagar S, Kumar A, et al. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol 2010;188:833-49.
38. Mittal A, Bhatnagar S, Kumar A, Paul PK, Kuang S, Kumar A. Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am J Pathol 2010;177:1732-42.
39. Panguluri SK, Bhatnagar S, Kumar A, et al. Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PLoS ONE 2010;5:e8760.
40. Bhatnagar S, Kumar A. The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr Mol Med 2012;12:3-13.
41. Li YP, Chen Y, John J, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005;19:362-70.
42. Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, Kandarian SC. Activation of an alternative NFkappaB pathway in skeletal muscle during disuse atrophy. FASEB J 2002;16:529-38.
43. Baltgalvis KA, Berger FG, Peña MM, Davis JM, White JP, Carson JA. Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc (Min/+) mouse. Pflugers Arch 2009;457:989-1001.
44. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 2006;119:526.e9-17.
45. Schaap LA, Pluijm SM, Deeg DJ, et al.; Health ABC Study. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci 2009;64: 1183-9.
46. Léger B, Derave W, De Bock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 2008;11:163-175B.
47. Hansen JA, Lindberg K, Hilton DJ, Nielsen JH, Billestrup N. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 1999;13:1832-43.
48. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001;233: 556-64.
49. Miller JT, Btaiche IF. Oxandrolone treatment in adults with severe thermal injury. Pharmacotherapy 2009;29: 213-26.
50. Przkora R, Herndon DN, Suman OE. The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. Pediatrics 2007;119:e109-16.